Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.

Natalia G ShcherbakovaGary TeresoJacqueline SpainRobert J Roose

Published in: The Annals of pharmacotherapy (2018)

Several health care delivery and use variables were significantly associated with nonpersistence. Concomitant use of prescription opioids is the most easily modifiable risk factor that health care providers and policy makers may act on to improve treatment continuation.

Keyphrases

healthcare
end stage renal disease
newly diagnosed
risk factors
chronic kidney disease
chronic pain
pain management
health insurance
affordable care act